A Leadership Perspective from Yvonne Lungershausen, CEO of Avance Clinical
In partnership with Frost & Sullivan, this executive insight explores how biotech CROs are evolving through AI, globalization, and patient-first models.
Key Takeaways
-
AI as a force multiplier: Streamlining everything from patient recruitment to regulatory submissions
-
Strategic expansion: M&A, APAC partnerships, and talent-driven growth
-
Tech with compliance: Innovation doesn’t have to compromise quality
-
Client-first culture: 70% retention rate driven by tailored service and scientific rigor
-
Vision for 2025: Smarter, faster trials — powered by people and technology
Coming on June 19
Discover how one biotech leader turned emerging modality ambiguity into long-term value. Our new case study reveals five strategic wins across gene therapy, mRNA, and more.
Download Now
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on store.frost.com.
*$1,000 honorarium is subject to eligibility
